Sage Therapeutics to Host “Sage FutureCast” Webcast
June 27 2019 - 6:30AM
Business Wire
Event will provide an R&D and portfolio
review across the depression, neurology and neuropsychiatric
franchises
Sage Therapeutics (NASDAQ: SAGE), a biopharmaceutical company
developing novel medicines to treat life-altering central nervous
system (CNS) disorders, today announced it will host “Sage
FutureCast: An R&D and Portfolio Review” on Wednesday, July 24,
2019 from 8 a.m. to 9:30 a.m. EDT.
Sage FutureCast will discuss the Company’s research and
development strategy, and review clinical progress in programs
throughout the depression, neurology and neuropsychiatric
franchises, including SAGE-217, SAGE-324 and SAGE-718,
respectively.
A live webcast of the presentations can be accessed on the
investor page of Sage's website at investor.sagerx.com. A replay of
the webcast will also be archived for up to 30 days on Sage's
website following the conference.
About Sage Therapeutics Sage Therapeutics is a
biopharmaceutical company committed to developing novel medicines
to transform the lives of patients with life-altering central
nervous system (CNS) disorders. Sage’s portfolio of novel compounds
targets critical receptor systems in the brain and includes the
first treatment specifically approved by the U.S. Food and Drug
Administration for postpartum depression as well as compounds being
developed as potential treatments for diseases such as major
depressive disorder, insomnia, bipolar disorder and essential
tremor. For more information, please visit www.sagerx.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190627005125/en/
Investor Contact Maren Killackey 617-949-4113
maren.killackey@sagerx.com
Media Contact Alexis Smith 617-588-3740
alexis.smith@sagerx.com
Sage Therapeutics (NASDAQ:SAGE)
Historical Stock Chart
From Aug 2024 to Sep 2024
Sage Therapeutics (NASDAQ:SAGE)
Historical Stock Chart
From Sep 2023 to Sep 2024